MetaCap

Aardvark Therapeutics (AARD) vs Rockwell Medical (RMTI)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Rockwell Medical (RMTI) has outperformed Aardvark Therapeutics (AARD) over the past year, losing 34.6% versus a loss of 90.2%. Rockwell Medical is the larger company by market cap ($23.1 million vs $20.2 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AARD-90.15%RMTI-34.61%
+77%-11%-98%
Nov 21, 20251 yearNov 20, 2026
AARD-93.06%RMTI-68.54%
+28%-35%-99%
Feb 10, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AARD versus RMTI key metrics
MetricAARDRMTI
Share price$0.9226$5.82
Market cap$20.20M$23.12M
1-day change-7.74%-7.03%
YTD return-92.97%-29.88%
1-year return-90.15%-34.61%
5-year return—-87.98%
Forward P/E—83.14
EPS (TTM)$-3.33$-1.43
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$69.26M
Revenue growth (YoY)—-31.76%
Net income (latest FY)$-57.59M$-5.31M
Gross margin—16.89%
Operating margin—-6.77%
Net margin—-7.67%
52-week high$16.60$12.90
52-week low$0.90$4.89
Distance from 52-week high-94.44%-54.88%
Analyst consensusbuynone
Avg. price target upside+1104.21%+243.64%
Average volume643.53K25.91K
Shares outstanding21.89M3.97M
Employees28157
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • RMTI has outperformed AARD by 55.5 percentage points over the past year.

About Aardvark Therapeutics

AARD stock →

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc.

Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees

About Rockwell Medical

RMTI stock →

Rockwell Medical, Inc., together with its subsidiaries, engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. It offers citrapure citric acid concentrate, dri-sate dry acid concentrate, renalpure liquid acid concentrate, dri-sate acid concentrate mixer, renalpure acid concentrate, renalpure bicarbonate concentrate, sterilyte bicarbonate concentrate, bicarbonate cartridges, and dry acid concentrate mixer, as well as ancillary products, including 5% acetic acid, cleaner, citric acid descaler, water softener salt pellets, and other supplies used by hemodialysis providers.

Health Care · Biotechnology: Pharmaceutical Preparations · 157 employees

AARD vs RMTI FAQ

Which is bigger, Aardvark Therapeutics or Rockwell Medical?

Rockwell Medical (RMTI) is larger, with a market capitalization of $23.12M compared with $20.20M for Aardvark Therapeutics (AARD).

Which stock has performed better over the past year, AARD or RMTI?

RMTI returned -34.61% over the past 12 months, compared with -90.15% for AARD (price return, excluding dividends). Past performance does not predict future results.

Are Aardvark Therapeutics and Rockwell Medical in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons